Top Markets
Coin of the day
Immunotech Biopharm Ltd Immunotech Biopharm Ltd

Immunotech Biopharm Ltd

6978
Rang in Aktien #27877
Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in... Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in cellular immunotherapy. Its primary activities involve the investigation, development, and market introduction of T cell-based immunotherapy solutions for various cancers within the People's Republic of China. The company's flagship product, EAL, is a multi-target cellular immunotherapy currently undergoing Phase II clinical trials for the purpose of preventing liver cancer recurrence after surgery. Furthermore, Immunotech Biopharm is conducting both preclinical and clinical research on EAL for its potential use in treating lung cancer, glioma, gastric cancer, and colorectal cancer. Other pipeline assets include the 6B11-OCIK injection, which is in Phase I trials for ovarian cancer; the CAR-T-19 injection product, targeting B-cell acute lymphoblastic leukaemia; and a range of TCR-T cell products designed for solid tumor treatment. Established in 2006, the company's main office is located in Beijing, China.
Aktienkurs
$0.04861197
Marktkapitalisierung
$30.02M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-91.39%
Land
CN
Handel Immunotech Biopharm Ltd (6978)

Kategorie

Aktien-Split-Historie für Immunotech Biopharm Ltd (6978)
Die Aktie Immunotech Biopharm Ltd (Symbol: 6978) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 20, 2026 statt.
Eine 6978-Aktie, die vor dem Aug 20, 2026 gekauft wurde, entspricht heute 0 6978-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
US
0 -
NL
1 x3
AU
0 -
CH